Skip to Main Content

Paper Details

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
J Clin Oncol
62
2022
B-cell receptor, Bevacizumab, Breast Cancer, Carboplatin, EFS, LTOs, Patients, RD, Triple-Negative, bevacizumab, cancer, cancers, carboplatin, cyclophosphamide, doxorubicin, mRNA, paclitaxel, patients, stage II-III, triple-negative breast cancer, tumor, tumor samples, tumor-infiltrating lymphocytes
Author NameAffiliation
Cheng FanLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Joel S Parker
Joel S Parker
Katherine A HoadleyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Katherine A HoadleyUniversity of North Carolina
Katherine A HoadleyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Katherine A HoadleyUniversity of North Carolina
Matthew G SolowayLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Sara M Tolaney
Cynthia X MaWashington University School of Medicine
Deborah Collyar
Clifford A HudisMemorial Sloan Kettering Cancer Center
Eric P Winer
Terry HyslopDuke University
Lisa A CareyUniversity of North Carolina at Chapel Hill
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Charles M PerouUniversity of North Carolina
  • 1 - 17

Datasets

Release 1.2